Histopathological study of epithelial ovarian tumors with special reference to human epidermal growth factor receptor-2/NEU and CA-125 expression

Shobnam Bahar Barbhuiya, Ananya Debnath, Monoj Kumar Deka, Shah Alam Sheikh


Background: Ovarian cancer is the second most common gynecologic malignancy. The aim of the study was to evaluate the tissue expression of HER-2/NEU and CA-125 in various epithelial ovarian carcinoma and assess the prognostic significance.

Methods: A retrospective study was done in 76 cases of ovarian tumor. IHC was done in 16 cases of epithelial ovarian cancer with HER-2/NEU and CA-125.

Results: Total number of cases were 76. Out of these 76 cases, 22 cases were malignant. 16 cases were malignant epithelial ovarian cancer. The highest incidence of malignant tumor was seen in the 41-50 years age group with 9 cases (11.84%). Out of 11 serous adenocarcinoma, 9 cases (81.8%) showed tissue expression of CA-125 and rest 2 cases (18.18%) did not show expression. All the 5 cases (100%) of mucinous adenocarcinoma did not show any tissue expression of CA-125. HER-2/NEU expression was positive in 7 out of 16 cases that is 43.75% and negative expression was seen in 9 out of 16 cases that is 56.25% of cases. Maximum HER-2/NEU positivity is seen among grade 3 tumors, that is (62.5%) (5 out of 8 cases).  

Conclusions: The incidence of epithelial ovarian tumors are more common. The tissue expression of CA-125 on malignant epithelial ovarian tumors was studied, which showed positive expression in serous cystadenocarcinomas, but not in mucinous cystadenocarcinoma. HER-2/NEU expression was seen to be increasing with advanced grade of the tumors.


Epithelial ovarian cancer, HER-2/NEU, CA-125

Full Text:



Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.

Basu P, De P, Mandal S, Ray K, Biswas J. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 2009;46(1):28-33.

Ellenson LH, Pirog EC. The female genital tract. In: Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran pathologic basis of disease. 9th ed. Philadelphia: Elsevier Saunders; 2015: 1022-1023.

Sarkar M, Jha T, Das TK, Sau V, Mitra S, Roy K. Spectrum of epithelial ovarian tumors with HER2/NEU expression by the carcinomas among patients admitted in a tertiary care hospital in Eastern India. Int J Med Sci Public Health. 2015;4(10):1388-92.

Goel S, Mehra M, Yadav A, Sharma M. A comparative study of HER2/NEU oncogene in benign and malignant ovarian tumors. Int J Scientific study. 2014;2(4):50-4.

Claudine R, Isabelle M, Denis L, Alain P. The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer. Ovarian cancer- basic science perspective. Europe: InTech; 2012: 67-84.

Gupta D, Christopher G. Role of CA125 in predicting ovarian cancer survival- a review of the epidemiological literature. J Ovarian Res. 2009;2:13.

Francisco C, Nadkarni N, Rebello M. Ovarian tumors in Goa: a clinicopathological study. J Obstet Gynecol India. 1993;43:408-12.

Rajan R. Analysis of ovarian pathologies in the modern perspective. Indian J Obstet Gynecol. 1994; 44:764-70.

Sarkar R. ovarian neoplasms- A 14 years study. Obstet Gynecol J India. 1996; 46:156-9.

Siriangkul S, Robbins KM, Silverberg SG. Ovarian mucinous tumors of low malignant potential. A clinicopathologic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol. 1995;14:198-208.

Fukazawa I, Inaba N, Ota Y, Sato N, Shivotake S, Iwasawa H, et al. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease. Arch Gynecol Obstet. 1988;243(1):41-50.

Neunteufel W, Breitenecker G. Tissue expression of CA125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Gynecol Oncol. 1989;32(3):297-302.

Ajani MA, Salami A, Awolude OA, Oluwasola AO, Akang EE. The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria. Southern African J Gynecol Oncol. 2016;8(1):9-13.

Marinas MC, Mogos G, Ciurea R, Mogos DG. EGFR, HER2/NEU and Ki67 immunoexpression in serous ovarian tumors. Rom J Morphol Embryol. 2012;53(3):563-7.

Vrabie CD, Petrescu A, Waller M, Dina I. Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol. 2008;49(3):327-38.

Mahdi MA. Overexpression of HER2/NEU in ovarian surface epithelial carcinoma in a sample of Iraqi patient at Al-kindy teaching hospital. Al-kindy Col Med J. 2013;9(1):126-32.